We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The latest in a series of setbacks has hit research on how effective the drug tenofovir is at stopping the HIV virus from infecting people in high-risk populations.

On 11 March, Family Health International announced it was cancelling tenofovir trials among Nigerian sex workers. The non-profit organisation cited problems with record keeping and other technical issues.

One day earlier, a separate trial of the drug due to take place in Thailand was criticised by local activists who claimed the research, involving injecting drug users, was unethical.

In 2004, Cambodia suspended trials of tenofovir following similar protests, and in February 2005, Cameroon also ended a trial of the drug (see Cameroon suspends trial of AIDS drug after protests).

Other trials of tenofovir are under way in Ghana and Malawi.

Link to full news story in Science

Read more about research ethics in SciDev.Net's ethics of research dossier.